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Anaphylaxis is a rare but serious adverse reaction that can occur following mRNA-based vaccination against coronavirus (COVID-19). This is a case of a geriatric patient presenting with
hypotension and an urticarial rash with bullous lesions following a syncopal episode with
incontinence. She received the second dose of the Pfizer-BioNTech (BNT162b2) COVID-19
vaccine three days prior, and first developed the skin abnormalities the morning after receiving the vaccine. She had no past history of anaphylaxis or allergies to vaccinations.
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Her presentation met the diagnostic criteria for anaphylaxis, according to the World Allergy
Organization: she had acute onset illness involving the skin and was hypotensive with symptoms suggestive of end-organ dysfunction. The latest literature published on anaphylaxis
to mRNA-based COVID-19 vaccination indicates that this is an extremely rare complication. From December 14, 2020, to January 18, 2021, 9 943 247 doses of the Pfizer-BioNTech
vaccine and 7 581 429 doses of the Moderna vaccine were administered in the United States.
Sixty-six of these patients met anaphylaxis criteria. Of these cases, 47 received the Pfizer
vaccine and 19 received the Moderna vaccine. Unfortunately, the mechanisms of these adverse reactions remain poorly understood, although it is postulated that particular vaccine
components such as polyethylene glycol or polysorbate 80 may be the underlying triggers.
This case demonstrates the importance of recognizing anaphylactic signs and symptoms,
as well as proper patient education about the benefits and potential, albeit rare, adverse
effects, of vaccination.
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Introduction

Vaccines play crucial roles in public health by
limiting or even eradicating infectious diseases
in populations. If most individuals are vaccinated, the entire population can be protected
through herd immunity, including those who
cannot be vaccinated or are immunocompromised.1 Amid the COVID-19 pandemic, the
swift advent of Food and Drug Administration
(FDA)-approved COVID-19 vaccination has
revolutionized healthcare and the safety of patients from diverse backgrounds. The Pfizer-BioNTech BNT162B2 mRNA and Moderna mRNA-

1273 COVID-19 vaccines received emergency
authorization for use by the United States
(US) FDA in December 2020.2 Public education regarding the safety profile of vaccination
and its rare but possible adverse effects is an
important pillar upholding community health. A
vaccine adverse event can be local or systemic,
instantaneous or relatively gradual. Anaphylaxis is one of these potential adverse outcomes
and is a life-threatening, immediate, systemic
reaction associated with immune reactions but
can be non-immune mediated or idiopathic in
etiology.1 This case documents an anaphylac-
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tic reaction following the second dose of the
Pfizer-BioNTech COVID-19 vaccine in a geriatric
female, with a discussion on the current literature describing such reactions to mRNA-based
COVID-19 vaccination and the latest research
investigating this phenomenon.

Case Description

The patient was a 66-year-old Hispanic female
with type 2 diabetes mellitus and hyperlipidemia who presented to the emergency department after an episode of syncope and an
unwitnessed fall. She had an episode of urinary
and fecal incontinence, which she noticed when
she regained consciousness. She has never had
a syncopal episode prior to this incident. On
initial presentation, her heart rate was 98 beats
per minute, her oxygen saturation was 100%
on room air, and her blood pressure was 74/40
mmHg. Upon physical examination, she had diffuse urticaria on her chest, abdomen, and face,
as well as bullous lesions, some ruptured, on
her extremities (Figure 1). She had received the
second dose of the Pfizer-BioNTech COVID-19
vaccine 3 days prior to the syncopal episode.
The morning after receiving the vaccination,
she developed urticaria and bullous lesions,
which did not improve with oral antihistamines.
She had no history of allergies or adverse
reactions to other types of vaccinations and
only experienced minor fatigue and chills after

A

receiving the first dose of the Pfizer-BioNTech
COVID-19 vaccine. Prior to the onset of symptoms, she had not consumed any new foods or
medications for the past several months and
endorsed good hydration. The second dose of
the Pfizer-BioNTech COVID-19 vaccine was the
only new medical therapy recently introduced.
She had no known sick contacts, and no change
in daily activity, clothing, linens, body wash, or
laundry detergent. She denied recent travel,
outdoor activity, or encounters with chemical
or environmental substances. She does not
own any pets and denied recent animal exposure or insect bites.
Complete blood count was significant for hemoglobin of 11.1 g/dL and a hematocrit of 28.6%
but was otherwise unremarkable. We found
she had an acute kidney injury, with a creatinine
of 2.04 mg/dL (baseline creatinine is approximately 0.80) and an estimated glomerular filtration rate of 24. Her chest x-ray and computed brain tomography showed no abnormalities.
We also performed a cardiac workup during her
hospital course. Her troponin I was elevated on
admission, 0.111 ng/mL, and decreased to 0.050
within 24 hours of admittance. Her electrocardiogram showed tachycardia and nonspecific
ST segment abnormalities. The echocardiogram was unremarkable. Her cardiac catheterization showed patent coronary arteries.

B

Figure 1. A. Diffuse urticaria is shown following the second dose of the Pfizer-BioNTech COVID-19
vaccine. B. Ruptured bullae shown on an upper extremity following the second dose of the Pfizer-BioNTech COVID-19 vaccine.
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We treated her with intravenous fluids, methylprednisolone, famotidine, and diphenhydramine. Her vital signs stabilized, renal function
returned to baseline, and her rash significantly
improved within a couple of days of initiating
treatment. We discharged her while she was on
oral famotidine, diphenhydramine, and prednisone. At her follow-up appointment a few
weeks later, the patient’s rash was completely
resolved, and she reported no further episodes
of lightheadedness or syncope.

Discussion

This case appears to be a rare instance of an
anaphylactic reaction that occurred following
the administration of the second dose of the
Pfizer-BioNTech COVID-19 vaccination. Anaphylaxis is an acute reaction involving multiple
organ systems and potentially leading to death.
Anaphylaxis primarily affects the pulmonary,
cardiovascular, and/or mucocutaneous systems.
Some classic manifestations include angioedema, wheezing, hypovolemia, distributive shock,
urticaria, pruritis, and flushing.3 Other associated signs and symptoms may include dizziness,
confusion, syncope, seizures, nausea, vomiting,
diarrhea, and urinary or fecal incontinence.
The mechanism of anaphylaxis is complex and
multifactorial. The traditional pathway involves
mediators such as interleukin-4, interleukin-5,
and B-cells producing IgE, which forms IgE-antigen complexes with the receptors on mast
cells and basophils.3 This crosslinking then
triggers degranulation of the mast cells and
basophils, thereby releasing both preformed
(eg, histamine, tryptase, chymase, heparin,
carboxypeptidase, tumor necrosis factor alpha) and newly synthesized (eg, leukotrienes,
platelet-activating factor, vascular endothelial
growth factor) mediators that cause the severe
and variable presentations of anaphylaxis.3
The second dose of the Pfizer-BioNTech
COVID-19 vaccine was considered a potential trigger of our patient’s symptoms after a
thorough history was collected. In addition to
genetic disorders predisposing some to anaphylaxis, numerous possible causes of anaphylaxis are found in daily life, including but not
limited to various foods, medications, animals,
exercise, textiles, and hormones.3 Thus, we attempted to collect extensive information from
the patient to formulate an appropriate history
of her present illness, inquiring about variables

such as her living situation, diet, medication
regimen, and travel history, among others. Although gathering a detailed timeline on these
variables from the past few days and the last
several weeks and months was challenging, the
patient fervently denied any lifestyle or medical
changes to the best of her knowledge. Receiving the Pfizer-BioNTech COVID-19 vaccine
was the only recent possible trigger she could
recall. Thus, the vaccination was considered a
potential cause of anaphylaxis, though there is
insufficient information to conclude it was the
sole or definitive trigger of her symptoms.
Despite this broad spectrum of manifestations,
the diagnosis of anaphylaxis is based on the
guidelines outlined by the World Allergy Organization (WAO). According to the WAO, there
is a high likelihood of anaphylaxis if the patient
presents with acute onset (minutes to hours)
illness involving the skin and/or mucosa with at
least one of the following: respiratory compromise, reduced blood pressure or associated
symptoms reflecting end-organ dysfunction,
or severe gastrointestinal symptoms.4 Even
without skin manifestations, a patient can also
meet the WAO criteria for likely anaphylaxis
if they present with acute onset hypotension,
bronchospasm, or laryngeal involvement after
being exposed to a known or probable allergen.4 This specific patient met the WAO criteria for anaphylaxis, as she developed acute skin
manifestations within hours of vaccination and
presented with hypotension and symptoms
of end-organ dysfunction (syncope, incontinence).4 Of note, systemic vasovagal reactions
can sometimes present similar characteristics
at first glance, but this patient’s comprehensive clinical picture was more consistent with a
true anaphylactic reaction. Systemic vasovagal
reactions almost always occur immediately or
within 30 minutes after exposure to a trigger.1
Additionally, vasovagal reactions are associated with a brief duration of hypotension that
swiftly resolves when supine, loss of consciousness that also quickly improves with positional
changes, and bradycardia.1 In contrast, this patient’s reaction did not occur within 30 minutes
of vaccination. She was tachycardic, and her hypotension and loss of consciousness were not
transient nor influenced by position. Moreover,
her skin manifestations, including erythematous, urticarial, and pruritic rashes, were not
systemic vasovagal reactions.1
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Anaphylaxis is a severe, life-threatening adverse
event of vaccination. However, the latest data
suggests the rates of anaphylactic reactions to
mRNA COVID-19 vaccination, for both Pfizer
and Moderna products, are low and should not
deter the general population from receiving
the benefits of vaccination. From December 14,
2020, to January 18, 2021, almost 10 million doses of the Pfizer-BioNTech vaccine and over 7
and a half million doses of the Moderna vaccine
were administered in the US.5 During this period, 66 cases reported to the Vaccine Adverse
Event Reporting System (VAERS) met the
Brighton Classification criteria for either level 1,
2, or 3 anaphylaxis.6 Of the 66 cases reported to
VAERS, 47 had received the Pfizer vaccine, and
19 had received the Moderna vaccine.5 The median duration of time to symptom onset was
approximately 10 minutes for both vaccines. Of
the reported cases meeting the criteria, 32%
had a previous episode of anaphylaxis secondary to other exposures. Of the 47 cases who
had anaphylaxis to the Pfizer-BioNTech vaccine,
the median age was 39, and 44 (94%) were female. Furthermore, 36 (77%) had a prior history
of allergic reactions, and 16 (34%) had at least
one previous episode of anaphylaxis.5
Studies looking specifically at the 2-dose series
of the Pfizer-BioNTech COVID-19 vaccination
have shown it to be highly effective and safe
for the majority of the population. In Polack
et al.’s multinational, placebo-controlled trial
published in December 2020, 21 720 participants received both doses of the BNT162b2
Pfizer vaccine (21 days apart), and 21 728 received a placebo.7 Among the 21 720 who were
vaccinated, 8 cases of COVID-19 occurred at
least 7 days after receiving the second dose. Of
the 21 728 who received a placebo, 162 cases of
COVID-19 were found.7 The FDA defines cases
of severe COVID-19 as confirmed COVID-19
with at least 1 of the following characteristics:
clinical signs at rest reflective of severe systemic disease, signs of shock, respiratory failure, marked acute renal, neurologic or hepatic
dysfunction, admission to the intensive care
unit, or death.1 There were 10 cases of severe
COVID-19 infection, with 9 coming from the
placebo group.7 Two vaccine recipients and 4
placebo recipients died. However, the investigators did not find any deaths related to the
vaccine, placebo, or COVID-19 illness.7 Within
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7 days of receiving the vaccine, less than 1%
reported severe pain. Most of the local reactions reported were mild-moderate and resolved within 2 days; no grade 4 local reactions
were reported.7 Another multisite US study
examined the safety of the second dose of the
Pfizer or Moderna vaccination in patients who
had an adverse reaction to the first dose. There
were 189 participants total, including 130 (69%)
receiving Moderna and 59 (31%) receiving Pfizer-BioNTech.8 All 159 participants who received
the second dose of the vaccine were found
to tolerate the dose, even the 19 who had a
reported reaction meeting anaphylaxis criteria
after their first dose.8 Although 32 (20%) had
immediate reactions, they were mild or resolved promptly with antihistamine therapy.8
Unfortunately, the underlying mechanism
and particular trigger of anaphylaxis in these
select patients are poorly understood. Further
research is needed before a definitive culprit
can be identified. In Warren et al.’s case series
involving 22 individuals who had a suspected
allergic reaction to COVID mRNA vaccines, skin
prick testing was performed with either polyethylene glycol (PEG) or polysorbate 80 (P80),
known components of the mRNA vaccines.9
Among the 11 patients who underwent skin
prick testing, zero were positive to PEG or P80,
and 1 out of 10 (10%) were positive to the same
manufacturer of vaccine they had received.9
However, these same 11 participants also underwent basophil activation testing; 10 of 11
(91%) had positive results to PEG, and 11 of 11
(100%) were positive to the component used in
the respective vaccine administered.9 These patients were found to have elevated levels of IgG
to PEG but no significant elevations in baseline
IgE levels. These results suggest that patients
who experience severe allergic reactions to the
COVID-19 mRNA vaccines may have an allergy
to PEG or P80.9 Furthermore, the immunoglobulin studies performed in this trial suggest that
a significant proportion of documented anaphylactic reactions to the COVID-19 vaccines
can be attributed to reactions to PEG in particular and may, in fact, be mediated through
non-IgE-related mechanisms, such as IgG-mediated complement-activated-related pseudoallergy.9 PEG is a hydrophilic polymer that is an
excipient in various products used in everyday
life and has recently had increasing recognition
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in the literature as a hidden high-risk allergen.
P80 can also induce similar reactions, as it
shares a chemical moiety with PEG.10
Although the overall rates of suspected severe
adverse reactions to the COVID-19 vaccination are low, patients who are at higher risk of
such complications should be identified and
provided the appropriate safety precautions.
To screen for populations at risk of reactions
to specific components of the vaccine, such
as PEG or P80, skin prick or intradermal testing, immunoglobulin assays, and basophil
activation testing as well as oral provocation
testing can be utilized.10 Patients at higher risk
of anaphylaxis include those who have a history of hypersensitivity reactions to vaccines,
anaphylaxis from any cause, mastocytosis, or
severe asthma. Such patients should receive
a premedication protocol and have prepared
transport to a hospital if they choose to receive
the vaccine.11 Patients who develop a suspected
severe allergic reaction to the first vaccination
could potentially undergo desensitization with
individual components of the vaccine or receive
their booster vaccination in incremental doses
instead, as the European Academy of Allergy
and Clinical Immunology points out.12 Such
endeavors will require close collaboration and
open disclosures of data between the medical
field and pharmaceutical industries before they
can be successfully implemented on a large
scale.12

Conclusion

This case may be a unique instance of a suspected anaphylactic reaction following the
second dose of the Pfizer-BioNTech COVID-19
vaccination in a patient who experienced minimal side effects to the first dose of the vaccine. This case demonstrates the importance of
appropriately recognizing possible anaphylactic
signs and symptoms and proper patient education about the benefits and potential, albeit
rare, severe adverse effects of vaccination.
Further research opportunities such as assessment of the mRNA COVID-19 vaccine’s longterm effects, reactions to additional boosters,
and testing for other vaccine components
possibly contributing to allergic responses
may help expand our understanding. Correctly
identifying the potential mechanisms and risk
factors of adverse vaccine reactions and expanding documentation of these in the medical

literature will ultimately lead to an improved
public awareness of vaccination safety.13
In order for patients to make fully-informed
decisions regarding their health amidst the
COVID-19 pandemic, appropriate education must be provided on the vaccine’s rare
but possible adverse events, associated risk
factors, and prevention efforts to strengthen
patient awareness in the future. In the modern era, vaccine misinformation can be readily
distributed throughout communities, especially impacting impoverished or minority populations.13 Although severe adverse effects to
vaccination are rare, it is essential to discuss
and receive complete and fully informed consent. Being fully informed allows the patient
to be aware and make an autonomous decision with knowledge of the benefits as well as
the potential harm.13
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